Pancreatic Cancer Research

ResearcherUniversity Hospital UlmActive in the last 2 years

Michael Geißler

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0265-8490; OpenAlex author ID A5064981456. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2012: 1 paper · 2013: 3 papers · 2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper

Papers 13

  1. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pan… Co-author DOI 10.1016/s2468-1253(24)00197-3↗
  2. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  3. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
  4. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, r… Co-author DOI 10.1186/s12885-018-5183-y↗
  5. Impact of SPARC expression on outcome in patients with advanced pancreatic cancer not receiving nab-paclitaxel: a pooled analysis from prospective clinical and… Co-author DOI 10.1038/bjc.2016.355↗
  6. DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-016-2052-4↗
  7. Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis fr… Co-author DOI 10.3109/0284186x.2015.1034877↗
  8. Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action. First author DOI 10.1159/000358890↗
  9. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. Co-author DOI 10.1186/1471-2407-14-624↗
  10. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-P… Co-author DOI 10.1038/bjc.2012.495↗
  11. [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
  12. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of … Co-author DOI 10.1136/gutjnl-2012-302759↗
  13. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Last author DOI 10.1038/bjc.2012.18↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Thomas Jens Ettrich · 5 shared papers, 2016–2024 · strength 0.47
  2. Anke Reinacher‐Schick · 5 shared papers, 2012–2024 · strength 0.45
  3. Thomas Theodor Werner Seufferlein · 5 shared papers, 2014–2023 · strength 0.37
  4. Volker Heinemann · 7 shared papers, 2012–2024 · strength 0.37
  5. Stefan Hubert Boeck · 7 shared papers, 2012–2024 · strength 0.37
  6. Volker Kunzmann · 2 shared papers, 2023–2024 · strength 0.28
  7. Eike Gallmeier · 3 shared papers, 2018–2023 · strength 0.25
  8. Andrea Tannapfel · 3 shared papers, 2018–2023 · strength 0.25
  9. Waldemar H. Uhl · 3 shared papers, 2018–2023 · strength 0.25
  10. Alexander Otto König · 3 shared papers, 2018–2023 · strength 0.25
  11. Hana Algül · 3 shared papers, 2018–2023 · strength 0.25
  12. Marko Kornmann · 3 shared papers, 2018–2023 · strength 0.25
  13. Lukas Perkhofer · 3 shared papers, 2016–2023 · strength 0.23
  14. Helmut Oettle · 2 shared papers, 2014–2024 · strength 0.23
  15. Patrick Michl · 2 shared papers, 2016–2024 · strength 0.21
  16. Dominik Paul Modest · 2 shared papers, 2015–2024 · strength 0.20
  17. Michael B. Ghadimi · 2 shared papers, 2019–2023 · strength 0.19
  18. Detlef Klaus Bartsch · 2 shared papers, 2019–2023 · strength 0.19
  19. Alexander Kleger · 2 shared papers, 2019–2023 · strength 0.19
  20. Helmut Friess · 2 shared papers, 2019–2023 · strength 0.19
  21. Andreas Wolfgang Berger · 3 shared papers, 2016–2019 · strength 0.19
  22. S Daum · 2 shared papers, 2018–2023 · strength 0.18
  23. Uwe A. Wittel · 2 shared papers, 2018–2023 · strength 0.18
  24. Frank Kullmann · 1 shared paper, 2024 · strength 0.16
  25. Oliver Waidmann · 1 shared paper, 2024 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.